InvestorsHub Logo
Followers 21
Posts 980
Boards Moderated 0
Alias Born 03/20/2019

Re: None

Wednesday, 01/08/2020 1:38:34 PM

Wednesday, January 08, 2020 1:38:34 PM

Post# of 426487
Cit says AMRN selloff unwarranted! read below.

Amarin selloff on UnitedHealth preferred list reports unwarranted, says Citi Citi analyst Joel Beatty attributes the selloff today in shares of Amarin (AMRN) to reports stating that UnitedHealth (UNH) dropped Vascepa from its preferred list for 2020. However, after comparing 2019 and 2020 documents for a few UnitedHealth plans, Beatty did not find any examples of changes in tiering or other preferential status for Vascepa. Payers likely haven't yet considered the new "game-changing" cardiovascular risk-reduction label for Vascepa that was granted in December, which leaves Vascepa with no relevant competitors, Beatty tells investors in an intraday research note. As a result, the analyst, who keeps a Neutral rating on Amarin, views today's share pullback as unwarranted. The move creates a lower entry point for those investors looking to buy the stock, says Beatty. Amarin in afternoon trading is down 6%, or $1.15, to $18.93.

Read more at:
https://thefly.com/landingPageNews.php?id=3014881

my comment: it would be great if IR can put out a release on this. SMH
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News